INTENSITY THERAPEUTICS, INC. - Common Stock, $0.0001 par value (INTS)

CUSIP: 45828J103

Q4 2024 13F Holders as of 31 Dec 2024

Type / Class
Equity / Common Stock, $0.0001 par value
Shares outstanding
48,324,727
Total 13F shares
2,720,161
Share change
+971,790
Total reported value
$4,790,715
Price per share
$1.76
Number of holders
20
Value change
+$1,642,568
Number of buys
6
Number of sells
8

Quarterly Holders Quick Answers

What is CUSIP 45828J103?
CUSIP 45828J103 identifies INTS - INTENSITY THERAPEUTICS, INC. - Common Stock, $0.0001 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of INTS - INTENSITY THERAPEUTICS, INC. - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
SAPIENT CAPITAL LLC
13F
Company
2.1%
1,010,753
$3,861,076 30 Sep 2024
13F
VANGUARD GROUP INC
13F
Company
0.43%
208,886
$797,945 30 Sep 2024
13F
BROWN ADVISORY INC
13F
Company
0.31%
148,109
$565,776 30 Sep 2024
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.13%
64,349
$245,837 30 Sep 2024
13F
Sigma Planning Corp
13F
Company
0.1%
47,744
$182,382 30 Sep 2024
13F
Mesirow Financial Investment Management, Inc.
13F
Company
0.09%
44,177
$168,756 30 Sep 2024
13F
BLAIR WILLIAM & CO/IL
13F
Company
0.08%
37,805
$144,415 30 Sep 2024
13F
GTS SECURITIES LLC
13F
Company
0.08%
37,288
$142,440 30 Sep 2024
13F
One Charles Private Wealth Services, LLC
13F
Company
0.07%
31,800
$121,476 30 Sep 2024
13F
BlackRock, Inc.
13F
Company
0.05%
22,113
$84,472 30 Sep 2024
13F
UBS Group AG
13F
Company
0.04%
20,609
$78,726 30 Sep 2024
13F
Rothschild Wealth LLC
13F
Company
0.04%
18,918
$72,267 30 Sep 2024
13F
Bison Wealth, LLC
13F
Company
0.04%
17,420
$66,544 30 Sep 2024
13F
STATE STREET CORP
13F
Company
0.03%
14,500
$55,390 30 Sep 2024
13F
COMMONWEALTH EQUITY SERVICES, LLC
13F
Company
0.02%
10,414
$40,000 30 Sep 2024
13F
WELLS FARGO & COMPANY/MN
13F
Company
0.01%
3,450
$13,179 30 Sep 2024
13F
Tower Research Capital LLC (TRC)
13F
Company
0%
1,169
$4,431 30 Sep 2024
13F
MORGAN STANLEY
13F
Company
0%
500
$1,910 30 Sep 2024
13F
BANK OF AMERICA CORP /DE/
13F
Company
0%
49
$187 30 Sep 2024
13F
JPMORGAN CHASE & CO
13F
Company
0%
17
$65 30 Sep 2024
13F

Institutional Holders of INTENSITY THERAPEUTICS, INC. - Common Stock, $0.0001 par value (INTS) as of Q4 2024

As of 31 Dec 2024, INTENSITY THERAPEUTICS, INC. - Common Stock, $0.0001 par value (INTS) was held by 20 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 2,720,161 shares. The largest 10 holders included ARMISTICE CAPITAL, LLC, SAPIENT CAPITAL LLC, VANGUARD GROUP INC, BROWN ADVISORY INC, GEODE CAPITAL MANAGEMENT, LLC, Sigma Planning Corp, BLAIR WILLIAM & CO/IL, One Charles Private Wealth Services, LLC, BlackRock, Inc., and Mesirow Financial Investment Management, Inc.. This page lists 20 institutional shareholders reporting positions in this security for the Q4 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q4 2024 vs Q3 2024 Across Filers

Q3 2024 holders
20
Q4 2024 holders
20
Holder diff
0
Investor Q3 2024 Shares Q4 2024 Shares Share Diff Share Chg % Q3 2024 Value $ Q4 2024 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .